MEDY-TOX INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 135,000 KRW | -1.39% |
|
+1.35% | -43.98% |
| Mar. 21 | Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 05 | South Korean Shares Close Marginally Lower on North Korea's Artillery Shells Firing | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,677,322 | 1,017,738 | 876,202 | 806,183 | 1,621,720 | 908,581 | - |
| Enterprise Value (EV) 2 | 1,758 | 1,109 | 914.6 | 903.4 | 1,622 | 966.8 | 937.1 |
| P/E ratio | 62.3 x | -32.8 x | 8.99 x | 22.3 x | 184 x | 21.3 x | 13.5 x |
| Yield | 0.27% | 0.57% | - | - | - | 0.82% | 0.9% |
| Capitalization / Revenue | 8.15 x | 7.23 x | 4.74 x | 4.13 x | 7.33 x | 3.61 x | 2.88 x |
| EV / Revenue | 8.54 x | 7.87 x | 4.95 x | 4.63 x | 7.33 x | 3.84 x | 2.97 x |
| EV / EBITDA | 39.7 x | -58 x | 17.6 x | 14.6 x | 49.6 x | 13.6 x | 8.81 x |
| EV / FCF | 139 x | -83.9 x | 373 x | 55.4 x | - | 181 x | 16.7 x |
| FCF Yield | 0.72% | -1.19% | 0.27% | 1.8% | - | 0.55% | 5.98% |
| Price to Book | 6.3 x | 4.02 x | 2.09 x | 1.8 x | - | 1.82 x | 1.72 x |
| Nbr of stocks (in thousands) | 6,453 | 6,412 | 6,393 | 6,298 | 6,729 | 6,730 | - |
| Reference price 3 | 259,929 | 158,730 | 137,048 | 128,000 | 241,000 | 135,000 | 135,000 |
| Announcement Date | 3/4/20 | 3/12/21 | 3/11/22 | 3/7/23 | 3/7/24 | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 205.9 | 140.8 | 184.9 | 195.1 | 221.1 | 251.9 | 315.6 |
| EBITDA 1 | 44.27 | -19.12 | 51.87 | 61.98 | 32.7 | 71.05 | 106.3 |
| EBIT 1 | 25.69 | -37.07 | 34.49 | 46.66 | 17.32 | 54.62 | 93.01 |
| Operating Margin | 12.48% | -26.32% | 18.66% | 23.92% | 7.83% | 21.68% | 29.47% |
| Earnings before Tax (EBT) 1 | 25.15 | -42.14 | 129.4 | 49.31 | 15.74 | 55.8 | 92.23 |
| Net income 1 | 26.21 | -29.01 | 96.16 | 37.57 | 9.642 | 43.44 | 70.86 |
| Net margin | 12.73% | -20.6% | 52.01% | 19.26% | 4.36% | 17.25% | 22.45% |
| EPS 2 | 4,172 | -4,841 | 15,243 | 5,750 | 1,311 | 6,336 | 10,029 |
| Free Cash Flow 3 | 12,682 | -13,217 | 2,452 | 16,304 | - | 5,333 | 56,000 |
| FCF margin | 6,159.42% | -9,385.15% | 1,326.31% | 8,356.93% | - | 2,117.11% | 17,741.57% |
| FCF Conversion (EBITDA) | 28,644.56% | - | 4,727.04% | 26,307.35% | - | 7,506.77% | 52,657.72% |
| FCF Conversion (Net income) | 48,395.22% | - | 2,549.86% | 43,399.26% | - | 12,276.06% | 79,033.76% |
| Dividend per Share 2 | 691.1 | 907.0 | - | - | - | 1,101 | 1,217 |
| Announcement Date | 3/4/20 | 3/12/21 | 3/11/22 | 3/7/23 | 3/7/24 | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 69.88 | 45.65 | 39.76 | 49.76 | 53.31 | 52.27 | 42.67 | 51.79 | 58.65 | 68 | 59.65 | 58.55 | 61.8 | 70.1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 33.91 | 0.5614 | - | 10.38 | 14.53 | 16.29 | 1.767 | 9.551 | 3.575 | 2.43 | 9.6 | 11.8 | 15.15 | 18.1 |
| Operating Margin | 48.53% | 1.23% | - | 20.85% | 27.25% | 31.17% | 4.14% | 18.44% | 6.1% | 3.57% | 16.09% | 20.15% | 24.51% | 25.82% |
| Earnings before Tax (EBT) 1 | 34.46 | -19.69 | - | 24.22 | 17.59 | 2.315 | - | 9.152 | 3.429 | -3.376 | 11 | 12.2 | 14.9 | 18.1 |
| Net income 1 | 20.62 | -107.4 | - | 19.23 | 13.21 | -0.57 | - | 8.979 | -2.323 | 12.08 | 8.4 | 9.3 | 11.4 | 13.9 |
| Net margin | 29.52% | -235.16% | - | 38.66% | 24.77% | -1.09% | - | 17.34% | -3.96% | 17.76% | 14.08% | 15.88% | 18.45% | 19.83% |
| EPS | - | - | 639.0 | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 3/11/22 | 5/16/22 | 8/12/22 | 11/9/22 | 3/7/23 | 5/15/23 | 8/7/23 | 11/8/23 | 3/7/24 | - | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | 80.6 | 91.2 | 38.4 | 97.2 | - | 58.2 | 28.5 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.821 x | -4.772 x | 0.7407 x | 1.568 x | - | 0.8192 x | 0.268 x |
| Free Cash Flow 2 | 12,682 | -13,217 | 2,452 | 16,304 | - | 5,333 | 56,000 |
| ROE (net income / shareholders' equity) | 10.2% | -11.4% | 29.7% | 8.96% | 2.12% | 9.03% | 13.7% |
| ROA (Net income/ Total Assets) | 6.42% | -6.52% | 18% | 6.31% | - | 6.47% | 9.46% |
| Assets 1 | 408.3 | 445.2 | 533.9 | 595.8 | - | 671.8 | 749 |
| Book Value Per Share 3 | 41,261 | 39,532 | 65,667 | 70,922 | - | 73,990 | 78,705 |
| Cash Flow per Share 3 | 5,366 | 4,570 | 3,266 | 4,191 | - | 7,613 | 10,860 |
| Capex 1 | 21 | 41.1 | 17.5 | 9.9 | - | 14.7 | 15 |
| Capex / Sales | 10.21% | 29.22% | 9.47% | 5.07% | - | 5.82% | 4.75% |
| Announcement Date | 3/4/20 | 3/12/21 | 3/11/22 | 3/7/23 | 3/7/24 | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
135,000
KRW
Average target price
296,000
KRW
Spread / Average Target
+119.26%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -43.98% | 656M | |
| -4.24% | 86.85B | |
| +2.76% | 40.16B | |
| -16.40% | 31.28B | |
| +57.86% | 25.27B | |
| -15.29% | 15.33B | |
| -9.12% | 11.96B | |
| -42.56% | 11.61B | |
| +6.89% | 8.83B | |
| -10.53% | 7.94B |
- Stock Market
- Equities
- A086900 Stock
- Financials Medy-Tox Inc.
